Carestream Health names David Westgate new chairman, president and CEO

Carestream Health announced Thursday, July 19, that David C. Westgate has been named the company’s new chairman, president and CEO.

“Our focus will be on delivering innovation that is life-changing—for patients, customers, employees, communities and other stakeholders—and we will grow our business for long-term success,” Westgate said in a prepared statement. “We are very excited about pursuing new product development road maps that will position us to meet the diverse needs of our customers in the markets we will serve. Customer satisfaction, continuous innovation and operational excellence will be fundamental to our culture and we are committed to being the very best at what we do.”

Westgate previously served as the CEO of Jason Industries. His predecessor, Kevin Holbert, will assist with the transition.

“Kevin Hobert has done an excellent job leading Carestream’s development into a worldwide leader in the medical and dental imaging fields, and has prepared the company for sustainable growth in the coming years,” Westgate said in the same statement. “I would like to thank Kevin for the many significant contributions he has made to Carestream’s success since launching the company more than 11 years ago.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.